» Articles » PMID: 28965855

MicroRNA-148a-3p Enhances Cisplatin Cytotoxicity in Gastric Cancer Through Mitochondrial Fission Induction and Cyto-protective Autophagy Suppression

Overview
Journal Cancer Lett
Specialty Oncology
Date 2017 Oct 3
PMID 28965855
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Cisplatin (CDDP) resistance is a major clinical problem associated with poor prognosis in gastric cancer (GC) patients. In this study, we performed integrated analysis of TCGA data from microRNAs (miRNAs) expression matrix of GC patients who received CDDP-based chemotherapy with GEO dataset which contains differential miRNAs expression profiles in CDDP-resistant and -sensitive cell lines. We identified miR-148a-3p downregulation as a key step involved in CDDP resistance. Using a cohort consisting 105 GC patients who received CDDP-based therapy, we found that miR-148a-3p downregulation was associated with a decrease in patients' disease-free survival (DFS, P = 0.0077). A series of experiment data demonstrated that: 1) miR-148a-3p was downregulated in CDDP-resistant GC cell lines; 2) miR-148a-3p reconstitution sensitized CDDP-resistant cells to CDDP treatment through promoting mitochondrial fission and decreasing AKAP1 expression level; 3) AKAP1 played a novel role in CDDP resistance by inhibiting P53-mediated DRP1 dephosphorylation; 4) miR-148a-3p reconstitution in CDDP-resistant cells inhibits the cyto-protective autophagy by suppressing RAB12 expression and mTOR1 activation. Taken together, our study demonstrates that miR-148a-3p could be a promising prognostic marker or therapeutic candidate for overcoming CDDP resistance in GC.

Citing Articles

Hsa_circ_0001756 drives gastric cancer glycolysis by increasing the expression and stability of PGK1 mRNA.

Qian L, Wang L, Chen H, Wang S, Hou Y, Xu L Front Immunol. 2025; 16:1511247.

PMID: 40051638 PMC: 11882586. DOI: 10.3389/fimmu.2025.1511247.


The role of mitochondrial biogenesis, mitochondrial dynamics and mitophagy in gastrointestinal tumors.

Liu Y, Wang H, Zhang S, Peng N, Hai S, Zhao H Cancer Cell Int. 2025; 25(1):46.

PMID: 39955547 PMC: 11829463. DOI: 10.1186/s12935-025-03685-2.


Exosomal miR-6126 as a novel therapeutic target for overcoming resistance of anti-cancer effect in hepatocellular carcinoma.

Hwang H, Kim J, Kim T, Han Y, Choi D, Cho S BMC Cancer. 2024; 24(1):1557.

PMID: 39702014 PMC: 11660897. DOI: 10.1186/s12885-024-13342-y.


MicroRNA-mediated autophagy and drug resistance in cancer: mechanisms and therapeutic strategies.

Wei J, Wang X, Yu D, Tu Y, Yu Y Discov Oncol. 2024; 15(1):662.

PMID: 39549162 PMC: 11569378. DOI: 10.1007/s12672-024-01525-9.


Circ_0008315 promotes tumorigenesis and cisplatin resistance and acts as a nanotherapeutic target in gastric cancer.

Fei Y, Cao D, Li Y, Wang Z, Dong R, Zhu M J Nanobiotechnology. 2024; 22(1):519.

PMID: 39210348 PMC: 11360491. DOI: 10.1186/s12951-024-02760-6.


References
1.
Guo S, Peng Z, Yang X, Fan K, Ye H, Li Z . miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. Int J Biol Sci. 2011; 7(5):567-74. PMC: 3088878. DOI: 10.7150/ijbs.7.567. View

2.
Dolma S, Selvadurai H, Lan X, Lee L, Kushida M, Voisin V . Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. Cancer Cell. 2016; 29(6):859-873. PMC: 5968455. DOI: 10.1016/j.ccell.2016.05.002. View

3.
Fujiwara N, Inoue J, Kawano T, Tanimoto K, Kozaki K, Inazawa J . miR-634 Activates the Mitochondrial Apoptosis Pathway and Enhances Chemotherapy-Induced Cytotoxicity. Cancer Res. 2015; 75(18):3890-901. DOI: 10.1158/0008-5472.CAN-15-0257. View

4.
Wu H, Ng R, Chen X, Steer C, Song G . MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut. 2015; 65(11):1850-1860. PMC: 4882277. DOI: 10.1136/gutjnl-2014-308430. View

5.
Ao X, Zou L, Wu Y . Regulation of autophagy by the Rab GTPase network. Cell Death Differ. 2014; 21(3):348-58. PMC: 3921601. DOI: 10.1038/cdd.2013.187. View